Glonghui, March 21丨Shengnuo Biopharmaceutical Co., Ltd. (688117.SH) announced that Chengdu Shengnuo Biopharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently received the “Chemical Ingredient Marketing Application Approval Notice” issued by the State Drug Administration. Cetrorelix acetate is a synthetic decapeptide. The formulation is an injectable gonadotropin-releasing hormone (GnRH) antagonist, which is used to assist reproduction and inhibit the surge of early progesterone. Research shows that cetrorelix acetate has good curative effects on diseases such as ovarian cancer, prostate cancer, uterine fibroids, and endometriosis, and also has a preventive effect on benign prostatic hypertrophy and ovarian hyperstimulation syndrome.
圣诺生物(688117.SH)：醋酸西曲瑞克原料药获得上市申请批准通知书
Shengnuo Biotech (688117.SH): Cetrorelix acetate API received approval notice for marketing application
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.